Title |
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, February 2019
|
DOI | 10.1007/s00262-019-02315-x |
Pubmed ID | |
Authors |
Martin Sebastian, Andreas Schröder, Birgit Scheel, Henoch S. Hong, Anke Muth, Lotta von Boehmer, Alfred Zippelius, Frank Mayer, Martin Reck, Djordje Atanackovic, Michael Thomas, Folker Schneller, Jan Stöhlmacher, Helga Bernhard, Andreas Gröschel, Thomas Lander, Jochen Probst, Tanja Strack, Volker Wiegand, Ulrike Gnad-Vogt, Karl-Josef Kallen, Ingmar Hoerr, Florian von der Muelbe, Mariola Fotin-Mleczek, Alexander Knuth, Sven D. Koch |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 20% |
United Kingdom | 2 | 20% |
Singapore | 1 | 10% |
Unknown | 5 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 160 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 22 | 14% |
Researcher | 17 | 11% |
Student > Bachelor | 15 | 9% |
Student > Master | 14 | 9% |
Other | 12 | 8% |
Other | 21 | 13% |
Unknown | 59 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 33 | 21% |
Medicine and Dentistry | 17 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
Immunology and Microbiology | 10 | 6% |
Agricultural and Biological Sciences | 10 | 6% |
Other | 18 | 11% |
Unknown | 61 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2024.
All research outputs
#1,769,834
of 25,328,635 outputs
Outputs from Cancer Immunology, Immunotherapy
#56
of 2,975 outputs
Outputs of similar age
#45,798
of 491,864 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#1
of 19 outputs
Altmetric has tracked 25,328,635 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,975 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 491,864 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.